Protease inhibitors (PIs)
Protease inhibitors interrupt HIV replication at a late stage in its life cycle. PIs bind the active site on the HIV enzyme known as protease. Protease cleaves the long inactive protein strands produced during viral protein synthesis into active viral component proteins. Without protease, those long strands remain inactive and the virion fails to mature.
Drugs in this class are associated with metabolic abnormalities including dyslipidemia, hyperglycemia, insulin resistance, lipodystrophy, etc.
|Atazanavir||Jaundice, elevated liver function tests (LFT), PR interval elongation|
|Darunavir||Rash, ⬆ LFTs,|
|Indinavir||Nephrolithiasis, jaundice, ⬆ LFTs, alopecia, insomnia, taste alteration|
|Nelfinavir||DNV, ⬆ LFTs, fatigue|
|Ritonavir/Lopinavir||Diarrhea, nausea, vomiting (DNV), dyslipidemai, ⬆ LFTs, taste alteration|
|Saquinavir||DNV, ⬆ LFTs, headache, oral ulceration|
|Tipranavir||DNV, ⬆ LFTs, rash, intracranial hemorrhage|
on the interactive diagram HIV
Virus: Anatomy and Physiology and review the Maturation phase.
Be ready to answer the following question:
Protease inhibitors interfere with maturation of HIV by cutting p55 and p160.